# Prestige Consumer Healthcare Inc. (PBH)

> Source: Nexqual · https://nexqual.com/PBH · data as of 2026-10-22 20:00 UTC · cite as "Nexqual, Prestige Consumer Healthcare Inc. (PBH), nexqual.com/PBH" · informational, not investment advice.

**Price:** USD 49.46 (+3.21% on the day) · last close of Oct 22, 2026; US market pre market, not a live price. Prev close 47.92 · day 47.5–49.64 · 52w 42.62–71.07 · market cap $2.34B · NYQ

## Key facts
- Last four reported quarters (through Jun 30, 2026): revenue $1.10B, net income $172M (15.6% margin), free cash flow $235M (SEC filings).
- Valuation: P/E 13.6x (avg 17.6x at the last 3 fiscal year-ends), EV/EBITDA 13.2x, net debt $1.93B.
- 2 of 80 tracked superinvestors hold PBH (13F, Q2 2026): 1 new, 1 added, 0 reduced, 0 unchanged.
- Insider open-market sales, last ~7 months: 4 Form 4 filings, $120K; 1 not under a Rule 10b5-1 plan ($66K); 0 by opportunistic insiders, 0 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
- Total return with dividends: 1Y -21.0% vs S&P 500 +14.9%; 5Y -16.5% vs S&P 500 +80.3%.
- Next earnings: 2026-11-05, EPS estimate USD 1.07, revenue estimate $329M.

## Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters)
| USD | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $1.09B | $1.13B | $1.13B | $1.14B | $1.09B | $1.10B |
| Gross profit | $621M | $625M | $624M | $634M | $596M | — |
| Operating income | $330M | -$22.4M | $342M | $337M | $309M | $290M |
| Net income | $205M | -$82.3M | $209M | $215M | $190M | $172M |
| EPS (diluted) | $4.04 | -$1.65 | $4.17 | $4.29 | $3.91 | — |
| Free cash flow | $250M | $222M | $239M | $243M | $246M | $235M |
| Gross margin | 57.1% | 55.4% | 55.5% | 55.8% | 54.7% | — |
| Operating margin | 30.4% | -2.0% | 30.4% | 29.6% | 28.4% | 26.3% |
| Net margin | 18.9% | -7.3% | 18.6% | 18.9% | 17.5% | 15.6% |
| Revenue growth | +15.2% | +3.8% | -0.2% | +1.1% | -4.3% | — |
| Cash + short-term investments | $27.2M | $58.5M | $46.5M | $97.9M | $63.9M | — |
| Total debt | $1.48B | $1.35B | $1.14B | $992M | $994M | — |
Fiscal years end Mar. EPS is split-adjusted.

## Valuation (price ÷ last four quarters, through Jun 30, 2026)
P/E 13.6x · P/S 2.1x · EV/EBITDA 13.2x · EV/Sales 3.9x · P/FCF 10.0x · P/B 1.2x · FCF yield 10.04% · Earnings yield 7.34% · Buyback yield (TTM) 5.19% · Net debt $1.93B · EV $4.27B
P/E at fiscal year-ends: Mar 2026 15.2x, Mar 2025 20.1x, Mar 2024 17.4x.

## Superinvestors (SEC 13F-HR, Q2 2026)
2 of 80 tracked investors hold PBH. Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| John Rogers | Ariel Investments | 2.29% | $230M | Added +13.9% |
| Lee Ainslie | Maverick Capital | 0.02% | $2.4M | New position |

## Insider sales (SEC Form 4, open-market, last ~7 months)
3 of 4 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.
| Trade date | Insider | Role | Shares | Value | % of holdings sold | 10b5-1 plan | Insider type |
|---|---|---|---|---|---|---|---|
| 2026-05-11 | Zerillo Jeffrey | Senior VP Operations | 351 | $18K | 0.8% | Yes | Too little history (no open-market trades in 2023 or 2024) |
| 2026-05-07 | Zerillo Jeffrey | Senior VP Operations | 305 | $17K | 0.7% | Yes | Too little history (no open-market trades in 2023 or 2024) |
| 2026-05-05 | Zerillo Jeffrey | Senior VP Operations | 1,207 | $66K | 2.7% | No | Too little history (no open-market trades in 2023 or 2024) |
| 2026-05-05 | Zerillo Jeffrey | Senior VP Operations | 346 | $19K | 0.8% | Yes | Too little history (no open-market trades in 2023 or 2024) |
% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-23) | 5Y (from 2021-10-18) |
|---|---|---|
| Total return | -21.0% | -16.5% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | -21.0% | -3.5% |
| Volatility (annualized) | 33.0% | 25.2% |
| Max drawdown | -36.2% (Feb 2026→Oct 2026) | -49.5% (May 2025→Sep 2026) |

## Peers (Drug Manufacturers - Specialty & Generic)
BHC (Bausch Health Companies Inc.) USD 6.49 +0.62% · SUPN (Supernus Pharmaceuticals, Inc.) USD 42.07 +2.09% · HCM (HUTCHMED (China) Limited) USD 14.28 -0.63% · LQDA (Liquidia Corporation) USD 39.69 +2.14% · AMLX (Amylyx Pharmaceuticals, Inc.) USD 28.57 -1.58% · INDV (Indivior Pharmaceuticals, Inc.) USD 35.33 +1.55%

## More
Full page: https://nexqual.com/PBH · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Revenue by business segment (quarter ended 2026-06-30)

| Line | Revenue | Share | YoY |
|---|---|---|---|
| North American OTC Healthcare | $226.2M | 85.1% | +6.4% |
| International OTC Healthcare | $39.5M | 14.9% | +6.9% |
| Total revenue | $265.7M | 100% | — |

## Revenue by product line (quarter ended 2026-06-30)

| Line | Revenue | Share | YoY |
|---|---|---|---|
| Net sales | $260.3M | 98.0% | +4.4% |
| Women's Health | $47.2M | 17.8% | -5.1% |
| — Pain Relief (part of Women's Health) | $26.2M | 9.9% | -3.8% |
| — Cough, Cold & Allergy (part of Women's Health) | $15.6M | 5.9% | +17.0% |
| — Other revenues (part of Women's Health) | $5.4M | 2.0% | +2032.9% |
| Gastrointestinal | $47.1M | 17.7% | +7.9% |
| Dermatologicals | $30.6M | 11.5% | +9.9% |
| Eye & Ear Care | $28.3M | 10.7% | +2.0% |
| Oral Care | $18.5M | 6.9% | +1.7% |
| Wellness, Sleep & Other | $12.6M | 4.7% | +165.7% |
| Total revenue | $265.7M | 100% | — |
The lines above cover 167.4% of total revenue.

## Revenue by region (fiscal year ended 2026-03-31)

| Line | Revenue | Share | YoY |
|---|---|---|---|
| United States | $850.4M | 78.1% | -5.3% |
| Non Us | $238.3M | 21.9% | -0.8% |
| Total revenue | $1.09B | 100% | — |

## Customer concentration

Period ended 2026-06-30: 19%, 16% of revenue from unnamed direct customers (10-Q, filed 2026-08-06).

## Company outlook (8-K filed 2026-08-06)

- "LaCorium's Dermal Therapy® brand is a leader in therapeutic skin care in Australia, and we anticipate strong sales growth under the Prestige Consumer Healthcare business model, driven by category growth, innovation, and continued geographic expansion." "We are raising our fiscal 2027 financial outlook for both revenue and EPS, entirely to account for the addition of these two businesses."
- "These acquisitions add nearly 20% to our revenue base and we expect the acquisitions to become increasingly accretive to profitability and cash flow as we move past the near-term and begin to realize business synergies and our brand growth objectives," Mr."

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends 2026-09-30) | $1.07 | $1.10 | -2.9% | $329.1M | 7 |
| Next quarter (ends 2026-12-31) | $1.24 | $1.25 | -0.7% | $353.1M | 7 |
| Current fiscal year (ends 2027-03-31) | $4.57 | $4.57 | -0.1% | $1.27B | 8 |
| Next fiscal year (ends 2028-03-31) | $5.08 | $5.01 | +1.4% | $1.35B | 8 |